,study_id,category,subcategory,value,group,group_description
0,0,milestone,STARTED,521,P1,Placebo
0,0,milestone,STARTED,541,P2,Remdesivir
0,0,milestone,Received Treatment,517,P1,Placebo
0,0,milestone,Received Treatment,531,P2,Remdesivir
0,0,milestone,COMPLETED,508,P1,Placebo
0,0,milestone,COMPLETED,517,P2,Remdesivir
0,0,milestone,NOT COMPLETED,13,P1,Placebo
0,0,milestone,NOT COMPLETED,24,P2,Remdesivir
0,0,withdrawal reason,Enrolled but not treated,4,P1,Placebo
0,0,withdrawal reason,Enrolled but not treated,10,P2,Remdesivir
0,0,withdrawal reason,Physician Decision,1,P1,Placebo
0,0,withdrawal reason,Physician Decision,0,P2,Remdesivir
0,0,withdrawal reason,Withdrawal by Subject,7,P1,Placebo
0,0,withdrawal reason,Withdrawal by Subject,9,P2,Remdesivir
0,0,withdrawal reason,Adverse Event,0,P1,Placebo
0,0,withdrawal reason,Adverse Event,4,P2,Remdesivir
0,0,withdrawal reason,Transferred to another hospital,1,P1,Placebo
0,0,withdrawal reason,Transferred to another hospital,1,P2,Remdesivir
0,0,age,<=18 years,0,B1,Placebo
0,0,age,<=18 years,0,B2,Remdesivir
0,0,age,<=18 years,0,B3,Total
0,0,age,Between 18 and 65 years,324,B1,Placebo
0,0,age,Between 18 and 65 years,354,B2,Remdesivir
0,0,age,Between 18 and 65 years,678,B3,Total
0,0,age,>=65 years,197,B1,Placebo
0,0,age,>=65 years,187,B2,Remdesivir
0,0,age,>=65 years,384,B3,Total
0,0,"sex: female, male",Female,189,B1,Placebo
0,0,"sex: female, male",Female,189,B2,Remdesivir
0,0,"sex: female, male",Female,378,B3,Total
0,0,"sex: female, male",Male,332,B1,Placebo
0,0,"sex: female, male",Male,352,B2,Remdesivir
0,0,"sex: female, male",Male,684,B3,Total
0,0,ethnicity (nih/omb),Hispanic or Latino,116,B1,Placebo
0,0,ethnicity (nih/omb),Hispanic or Latino,134,B2,Remdesivir
0,0,ethnicity (nih/omb),Hispanic or Latino,250,B3,Total
0,0,ethnicity (nih/omb),Not Hispanic or Latino,373,B1,Placebo
0,0,ethnicity (nih/omb),Not Hispanic or Latino,382,B2,Remdesivir
0,0,ethnicity (nih/omb),Not Hispanic or Latino,755,B3,Total
0,0,ethnicity (nih/omb),Unknown or Not Reported,32,B1,Placebo
0,0,ethnicity (nih/omb),Unknown or Not Reported,25,B2,Remdesivir
0,0,ethnicity (nih/omb),Unknown or Not Reported,57,B3,Total
0,0,race (nih/omb),American Indian or Alaska Native,3,B1,Placebo
0,0,race (nih/omb),American Indian or Alaska Native,4,B2,Remdesivir
0,0,race (nih/omb),American Indian or Alaska Native,7,B3,Total
0,0,race (nih/omb),Asian,56,B1,Placebo
0,0,race (nih/omb),Asian,79,B2,Remdesivir
0,0,race (nih/omb),Asian,135,B3,Total
0,0,race (nih/omb),Native Hawaiian or Other Pacific Islander,2,B1,Placebo
0,0,race (nih/omb),Native Hawaiian or Other Pacific Islander,2,B2,Remdesivir
0,0,race (nih/omb),Native Hawaiian or Other Pacific Islander,4,B3,Total
0,0,race (nih/omb),Black or African American,117,B1,Placebo
0,0,race (nih/omb),Black or African American,109,B2,Remdesivir
0,0,race (nih/omb),Black or African American,226,B3,Total
0,0,race (nih/omb),White,287,B1,Placebo
0,0,race (nih/omb),White,279,B2,Remdesivir
0,0,race (nih/omb),White,566,B3,Total
0,0,race (nih/omb),More than one race,1,B1,Placebo
0,0,race (nih/omb),More than one race,2,B2,Remdesivir
0,0,race (nih/omb),More than one race,3,B3,Total
0,0,race (nih/omb),Unknown or Not Reported,55,B1,Placebo
0,0,race (nih/omb),Unknown or Not Reported,66,B2,Remdesivir
0,0,race (nih/omb),Unknown or Not Reported,121,B3,Total
0,0,enrollment region,Greece,19,B1,Placebo
0,0,enrollment region,Greece,14,B2,Remdesivir
0,0,enrollment region,Greece,33,B3,Total
0,0,enrollment region,South Korea,12,B1,Placebo
0,0,enrollment region,South Korea,9,B2,Remdesivir
0,0,enrollment region,South Korea,21,B3,Total
0,0,enrollment region,Singapore,7,B1,Placebo
0,0,enrollment region,Singapore,9,B2,Remdesivir
0,0,enrollment region,Singapore,16,B3,Total
0,0,enrollment region,United States,410,B1,Placebo
0,0,enrollment region,United States,427,B2,Remdesivir
0,0,enrollment region,United States,837,B3,Total
0,0,enrollment region,Japan,7,B1,Placebo
0,0,enrollment region,Japan,8,B2,Remdesivir
0,0,enrollment region,Japan,15,B3,Total
0,0,enrollment region,Denmark,21,B1,Placebo
0,0,enrollment region,Denmark,22,B2,Remdesivir
0,0,enrollment region,Denmark,43,B3,Total
0,0,enrollment region,Mexico,6,B1,Placebo
0,0,enrollment region,Mexico,4,B2,Remdesivir
0,0,enrollment region,Mexico,10,B3,Total
0,0,enrollment region,United Kingdom,21,B1,Placebo
0,0,enrollment region,United Kingdom,25,B2,Remdesivir
0,0,enrollment region,United Kingdom,46,B3,Total
0,0,enrollment region,Germany,6,B1,Placebo
0,0,enrollment region,Germany,7,B2,Remdesivir
0,0,enrollment region,Germany,13,B3,Total
0,0,enrollment region,Spain,12,B1,Placebo
0,0,enrollment region,Spain,16,B2,Remdesivir
0,0,enrollment region,Spain,28,B3,Total
0,0,Disease severity,Mild-to-moderate disease severity,50,B1,Placebo
0,0,Disease severity,Mild-to-moderate disease severity,55,B2,Remdesivir
0,0,Disease severity,Mild-to-moderate disease severity,105,B3,Total
0,0,Disease severity,Severe disease severity,471,B1,Placebo
0,0,Disease severity,Severe disease severity,486,B2,Remdesivir
0,0,Disease severity,Severe disease severity,957,B3,Total
0,1,milestone,STARTED,199,P1,Part A: Remdesivir (RDV) for 5 Days
0,1,milestone,STARTED,197,P2,Part A: Remdesivir for 10 Days
0,1,milestone,STARTED,200,P3,Part A: SOC Therapy
0,1,milestone,STARTED,517,P4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,milestone,COMPLETED,179,P1,Part A: Remdesivir (RDV) for 5 Days
0,1,milestone,COMPLETED,176,P2,Part A: Remdesivir for 10 Days
0,1,milestone,COMPLETED,178,P3,Part A: SOC Therapy
0,1,milestone,COMPLETED,437,P4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,milestone,NOT COMPLETED,20,P1,Part A: Remdesivir (RDV) for 5 Days
0,1,milestone,NOT COMPLETED,21,P2,Part A: Remdesivir for 10 Days
0,1,milestone,NOT COMPLETED,22,P3,Part A: SOC Therapy
0,1,milestone,NOT COMPLETED,80,P4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,withdrawal reason,Lost to Follow-up,8,P1,Part A: Remdesivir (RDV) for 5 Days
0,1,withdrawal reason,Lost to Follow-up,12,P2,Part A: Remdesivir for 10 Days
0,1,withdrawal reason,Lost to Follow-up,12,P3,Part A: SOC Therapy
0,1,withdrawal reason,Lost to Follow-up,48,P4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,withdrawal reason,Death,2,P1,Part A: Remdesivir (RDV) for 5 Days
0,1,withdrawal reason,Death,2,P2,Part A: Remdesivir for 10 Days
0,1,withdrawal reason,Death,4,P3,Part A: SOC Therapy
0,1,withdrawal reason,Death,12,P4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,withdrawal reason,Withdrew Consent,2,P1,Part A: Remdesivir (RDV) for 5 Days
0,1,withdrawal reason,Withdrew Consent,2,P2,Part A: Remdesivir for 10 Days
0,1,withdrawal reason,Withdrew Consent,5,P3,Part A: SOC Therapy
0,1,withdrawal reason,Withdrew Consent,6,P4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,withdrawal reason,Non-Compliance with Study Drug,0,P1,Part A: Remdesivir (RDV) for 5 Days
0,1,withdrawal reason,Non-Compliance with Study Drug,1,P2,Part A: Remdesivir for 10 Days
0,1,withdrawal reason,Non-Compliance with Study Drug,0,P3,Part A: SOC Therapy
0,1,withdrawal reason,Non-Compliance with Study Drug,0,P4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,withdrawal reason,Protocol Violation,0,P1,Part A: Remdesivir (RDV) for 5 Days
0,1,withdrawal reason,Protocol Violation,0,P2,Part A: Remdesivir for 10 Days
0,1,withdrawal reason,Protocol Violation,1,P3,Part A: SOC Therapy
0,1,withdrawal reason,Protocol Violation,0,P4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,withdrawal reason,Randomized but not Treated,8,P1,Part A: Remdesivir (RDV) for 5 Days
0,1,withdrawal reason,Randomized but not Treated,4,P2,Part A: Remdesivir for 10 Days
0,1,withdrawal reason,Randomized but not Treated,0,P3,Part A: SOC Therapy
0,1,withdrawal reason,Randomized but not Treated,14,P4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,"age, customized",< 65 Years,142,B1,Part A: Remdesivir for 5 Days
0,1,"age, customized",< 65 Years,141,B2,Part A: Remdesivir for 10 Days
0,1,"age, customized",< 65 Years,142,B3,Part A: SOC Therapy
0,1,"age, customized",< 65 Years,351,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,"age, customized",< 65 Years,776,B5,Total
0,1,"age, customized",>= 65 Years,49,B1,Part A: Remdesivir for 5 Days
0,1,"age, customized",>= 65 Years,52,B2,Part A: Remdesivir for 10 Days
0,1,"age, customized",>= 65 Years,58,B3,Part A: SOC Therapy
0,1,"age, customized",>= 65 Years,152,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,"age, customized",>= 65 Years,311,B5,Total
0,1,"sex: female, male",Female,77,B1,Part A: Remdesivir for 5 Days
0,1,"sex: female, male",Female,75,B2,Part A: Remdesivir for 10 Days
0,1,"sex: female, male",Female,75,B3,Part A: SOC Therapy
0,1,"sex: female, male",Female,221,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,"sex: female, male",Female,448,B5,Total
0,1,"sex: female, male",Male,114,B1,Part A: Remdesivir for 5 Days
0,1,"sex: female, male",Male,118,B2,Part A: Remdesivir for 10 Days
0,1,"sex: female, male",Male,125,B3,Part A: SOC Therapy
0,1,"sex: female, male",Male,282,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,"sex: female, male",Male,639,B5,Total
0,1,"race/ethnicity, customized",American Indian or Alaska Native,2,B1,Part A: Remdesivir for 5 Days
0,1,"race/ethnicity, customized",American Indian or Alaska Native,0,B2,Part A: Remdesivir for 10 Days
0,1,"race/ethnicity, customized",American Indian or Alaska Native,1,B3,Part A: SOC Therapy
0,1,"race/ethnicity, customized",American Indian or Alaska Native,3,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,"race/ethnicity, customized",American Indian or Alaska Native,6,B5,Total
0,1,"race/ethnicity, customized",Asian,34,B1,Part A: Remdesivir for 5 Days
0,1,"race/ethnicity, customized",Asian,31,B2,Part A: Remdesivir for 10 Days
0,1,"race/ethnicity, customized",Asian,37,B3,Part A: SOC Therapy
0,1,"race/ethnicity, customized",Asian,61,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,"race/ethnicity, customized",Asian,163,B5,Total
0,1,"race/ethnicity, customized",Black,35,B1,Part A: Remdesivir for 5 Days
0,1,"race/ethnicity, customized",Black,37,B2,Part A: Remdesivir for 10 Days
0,1,"race/ethnicity, customized",Black,27,B3,Part A: SOC Therapy
0,1,"race/ethnicity, customized",Black,107,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,"race/ethnicity, customized",Black,206,B5,Total
0,1,"race/ethnicity, customized",Native Hawaiian or Pacific Islander,1,B1,Part A: Remdesivir for 5 Days
0,1,"race/ethnicity, customized",Native Hawaiian or Pacific Islander,1,B2,Part A: Remdesivir for 10 Days
0,1,"race/ethnicity, customized",Native Hawaiian or Pacific Islander,1,B3,Part A: SOC Therapy
0,1,"race/ethnicity, customized",Native Hawaiian or Pacific Islander,1,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,"race/ethnicity, customized",Native Hawaiian or Pacific Islander,4,B5,Total
0,1,"race/ethnicity, customized",White,109,B1,Part A: Remdesivir for 5 Days
0,1,"race/ethnicity, customized",White,107,B2,Part A: Remdesivir for 10 Days
0,1,"race/ethnicity, customized",White,112,B3,Part A: SOC Therapy
0,1,"race/ethnicity, customized",White,260,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,"race/ethnicity, customized",White,588,B5,Total
0,1,"race/ethnicity, customized",Not Permitted,5,B1,Part A: Remdesivir for 5 Days
0,1,"race/ethnicity, customized",Not Permitted,5,B2,Part A: Remdesivir for 10 Days
0,1,"race/ethnicity, customized",Not Permitted,7,B3,Part A: SOC Therapy
0,1,"race/ethnicity, customized",Not Permitted,21,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,"race/ethnicity, customized",Not Permitted,38,B5,Total
0,1,"race/ethnicity, customized",Other,5,B1,Part A: Remdesivir for 5 Days
0,1,"race/ethnicity, customized",Other,12,B2,Part A: Remdesivir for 10 Days
0,1,"race/ethnicity, customized",Other,15,B3,Part A: SOC Therapy
0,1,"race/ethnicity, customized",Other,50,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,"race/ethnicity, customized",Other,82,B5,Total
0,1,"race/ethnicity, customized",Hispanic or Latino,25,B1,Part A: Remdesivir for 5 Days
0,1,"race/ethnicity, customized",Hispanic or Latino,42,B2,Part A: Remdesivir for 10 Days
0,1,"race/ethnicity, customized",Hispanic or Latino,34,B3,Part A: SOC Therapy
0,1,"race/ethnicity, customized",Hispanic or Latino,156,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,"race/ethnicity, customized",Hispanic or Latino,257,B5,Total
0,1,"race/ethnicity, customized",Not Hispanic or Latino,162,B1,Part A: Remdesivir for 5 Days
0,1,"race/ethnicity, customized",Not Hispanic or Latino,144,B2,Part A: Remdesivir for 10 Days
0,1,"race/ethnicity, customized",Not Hispanic or Latino,152,B3,Part A: SOC Therapy
0,1,"race/ethnicity, customized",Not Hispanic or Latino,325,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,"race/ethnicity, customized",Not Hispanic or Latino,783,B5,Total
0,1,"race/ethnicity, customized",Not Permitted,4,B1,Part A: Remdesivir for 5 Days
0,1,"race/ethnicity, customized",Not Permitted,7,B2,Part A: Remdesivir for 10 Days
0,1,"race/ethnicity, customized",Not Permitted,13,B3,Part A: SOC Therapy
0,1,"race/ethnicity, customized",Not Permitted,22,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,"race/ethnicity, customized",Not Permitted,46,B5,Total
0,1,"race/ethnicity, customized",Missing,0,B1,Part A: Remdesivir for 5 Days
0,1,"race/ethnicity, customized",Missing,0,B2,Part A: Remdesivir for 10 Days
0,1,"race/ethnicity, customized",Missing,1,B3,Part A: SOC Therapy
0,1,"race/ethnicity, customized",Missing,0,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,"race/ethnicity, customized",Missing,1,B5,Total
0,1,enrollment region,United States,76,B1,Part A: Remdesivir for 5 Days
0,1,enrollment region,United States,99,B2,Part A: Remdesivir for 10 Days
0,1,enrollment region,United States,85,B3,Part A: SOC Therapy
0,1,enrollment region,United States,318,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,enrollment region,United States,578,B5,Total
0,1,enrollment region,Spain,37,B1,Part A: Remdesivir for 5 Days
0,1,enrollment region,Spain,28,B2,Part A: Remdesivir for 10 Days
0,1,enrollment region,Spain,31,B3,Part A: SOC Therapy
0,1,enrollment region,Spain,44,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,enrollment region,Spain,140,B5,Total
0,1,enrollment region,Italy,30,B1,Part A: Remdesivir for 5 Days
0,1,enrollment region,Italy,23,B2,Part A: Remdesivir for 10 Days
0,1,enrollment region,Italy,26,B3,Part A: SOC Therapy
0,1,enrollment region,Italy,54,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,enrollment region,Italy,133,B5,Total
0,1,enrollment region,United Kingdom,7,B1,Part A: Remdesivir for 5 Days
0,1,enrollment region,United Kingdom,9,B2,Part A: Remdesivir for 10 Days
0,1,enrollment region,United Kingdom,17,B3,Part A: SOC Therapy
0,1,enrollment region,United Kingdom,27,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,enrollment region,United Kingdom,60,B5,Total
0,1,enrollment region,South Korea,7,B1,Part A: Remdesivir for 5 Days
0,1,enrollment region,South Korea,4,B2,Part A: Remdesivir for 10 Days
0,1,enrollment region,South Korea,10,B3,Part A: SOC Therapy
0,1,enrollment region,South Korea,16,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,enrollment region,South Korea,37,B5,Total
0,1,enrollment region,Germany,8,B1,Part A: Remdesivir for 5 Days
0,1,enrollment region,Germany,6,B2,Part A: Remdesivir for 10 Days
0,1,enrollment region,Germany,8,B3,Part A: SOC Therapy
0,1,enrollment region,Germany,13,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,enrollment region,Germany,35,B5,Total
0,1,enrollment region,Singapore,3,B1,Part A: Remdesivir for 5 Days
0,1,enrollment region,Singapore,6,B2,Part A: Remdesivir for 10 Days
0,1,enrollment region,Singapore,9,B3,Part A: SOC Therapy
0,1,enrollment region,Singapore,14,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,enrollment region,Singapore,32,B5,Total
0,1,enrollment region,Hong Kong,9,B1,Part A: Remdesivir for 5 Days
0,1,enrollment region,Hong Kong,11,B2,Part A: Remdesivir for 10 Days
0,1,enrollment region,Hong Kong,7,B3,Part A: SOC Therapy
0,1,enrollment region,Hong Kong,1,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,enrollment region,Hong Kong,28,B5,Total
0,1,enrollment region,Switzerland,4,B1,Part A: Remdesivir for 5 Days
0,1,enrollment region,Switzerland,5,B2,Part A: Remdesivir for 10 Days
0,1,enrollment region,Switzerland,6,B3,Part A: SOC Therapy
0,1,enrollment region,Switzerland,3,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,enrollment region,Switzerland,18,B5,Total
0,1,enrollment region,France,2,B1,Part A: Remdesivir for 5 Days
0,1,enrollment region,France,1,B2,Part A: Remdesivir for 10 Days
0,1,enrollment region,France,0,B3,Part A: SOC Therapy
0,1,enrollment region,France,5,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,enrollment region,France,8,B5,Total
0,1,enrollment region,Taiwan,5,B1,Part A: Remdesivir for 5 Days
0,1,enrollment region,Taiwan,1,B2,Part A: Remdesivir for 10 Days
0,1,enrollment region,Taiwan,0,B3,Part A: SOC Therapy
0,1,enrollment region,Taiwan,0,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,enrollment region,Taiwan,6,B5,Total
0,1,enrollment region,Netherlands,3,B1,Part A: Remdesivir for 5 Days
0,1,enrollment region,Netherlands,0,B2,Part A: Remdesivir for 10 Days
0,1,enrollment region,Netherlands,1,B3,Part A: SOC Therapy
0,1,enrollment region,Netherlands,1,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,enrollment region,Netherlands,5,B5,Total
0,1,enrollment region,Japan,0,B1,Part A: Remdesivir for 5 Days
0,1,enrollment region,Japan,0,B2,Part A: Remdesivir for 10 Days
0,1,enrollment region,Japan,0,B3,Part A: SOC Therapy
0,1,enrollment region,Japan,4,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,enrollment region,Japan,4,B5,Total
0,1,enrollment region,Sweden,0,B1,Part A: Remdesivir for 5 Days
0,1,enrollment region,Sweden,0,B2,Part A: Remdesivir for 10 Days
0,1,enrollment region,Sweden,0,B3,Part A: SOC Therapy
0,1,enrollment region,Sweden,3,B4,"Part B: Extension Treatment, Remdesivir for 10 Days"
0,1,enrollment region,Sweden,3,B5,Total
0,2,milestone,STARTED,200,P1,Part A: Remdesivir (RDV) for 5 Days
0,2,milestone,STARTED,197,P2,Part A: Remdesivir for 10 Days
0,2,milestone,STARTED,844,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,milestone,STARTED,3597,P4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,milestone,COMPLETED,168,P1,Part A: Remdesivir (RDV) for 5 Days
0,2,milestone,COMPLETED,164,P2,Part A: Remdesivir for 10 Days
0,2,milestone,COMPLETED,621,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,milestone,COMPLETED,2952,P4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,milestone,NOT COMPLETED,32,P1,Part A: Remdesivir (RDV) for 5 Days
0,2,milestone,NOT COMPLETED,33,P2,Part A: Remdesivir for 10 Days
0,2,milestone,NOT COMPLETED,223,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,milestone,NOT COMPLETED,645,P4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,withdrawal reason,Death,21,P1,Part A: Remdesivir (RDV) for 5 Days
0,2,withdrawal reason,Death,28,P2,Part A: Remdesivir for 10 Days
0,2,withdrawal reason,Death,188,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,withdrawal reason,Death,371,P4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,withdrawal reason,Lost to Follow-up,8,P1,Part A: Remdesivir (RDV) for 5 Days
0,2,withdrawal reason,Lost to Follow-up,4,P2,Part A: Remdesivir for 10 Days
0,2,withdrawal reason,Lost to Follow-up,22,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,withdrawal reason,Lost to Follow-up,235,P4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,withdrawal reason,Withdrew consent,1,P1,Part A: Remdesivir (RDV) for 5 Days
0,2,withdrawal reason,Withdrew consent,0,P2,Part A: Remdesivir for 10 Days
0,2,withdrawal reason,Withdrew consent,11,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,withdrawal reason,Withdrew consent,32,P4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,withdrawal reason,Adverse Event,2,P1,Part A: Remdesivir (RDV) for 5 Days
0,2,withdrawal reason,Adverse Event,1,P2,Part A: Remdesivir for 10 Days
0,2,withdrawal reason,Adverse Event,2,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,withdrawal reason,Adverse Event,2,P4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,withdrawal reason,Investigator's Discretion,0,P1,Part A: Remdesivir (RDV) for 5 Days
0,2,withdrawal reason,Investigator's Discretion,0,P2,Part A: Remdesivir for 10 Days
0,2,withdrawal reason,Investigator's Discretion,0,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,withdrawal reason,Investigator's Discretion,3,P4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,withdrawal reason,Non-compliance With Study Drug,0,P1,Part A: Remdesivir (RDV) for 5 Days
0,2,withdrawal reason,Non-compliance With Study Drug,0,P2,Part A: Remdesivir for 10 Days
0,2,withdrawal reason,Non-compliance With Study Drug,0,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,withdrawal reason,Non-compliance With Study Drug,1,P4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,withdrawal reason,Protocol Violation,0,P1,Part A: Remdesivir (RDV) for 5 Days
0,2,withdrawal reason,Protocol Violation,0,P2,Part A: Remdesivir for 10 Days
0,2,withdrawal reason,Protocol Violation,0,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,withdrawal reason,Protocol Violation,1,P4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,"age, customized",< 65,116,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,"age, customized",< 65,113,B2,Part A: Remdesivir for 10 Days
0,2,"age, customized",< 65,581,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,"age, customized",< 65,2399,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,"age, customized",< 65,3209,B5,Total
0,2,"age, customized",≥ 65,84,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,"age, customized",≥ 65,84,B2,Part A: Remdesivir for 10 Days
0,2,"age, customized",≥ 65,263,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,"age, customized",≥ 65,1198,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,"age, customized",≥ 65,1629,B5,Total
0,2,"sex: female, male",Female,80,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,"sex: female, male",Female,64,B2,Part A: Remdesivir for 10 Days
0,2,"sex: female, male",Female,312,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,"sex: female, male",Female,1351,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,"sex: female, male",Female,1807,B5,Total
0,2,"sex: female, male",Male,120,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,"sex: female, male",Male,133,B2,Part A: Remdesivir for 10 Days
0,2,"sex: female, male",Male,532,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,"sex: female, male",Male,2246,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,"sex: female, male",Male,3031,B5,Total
0,2,"race/ethnicity, customized",American Indian or Alaska Native,2,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,"race/ethnicity, customized",American Indian or Alaska Native,0,B2,Part A: Remdesivir for 10 Days
0,2,"race/ethnicity, customized",American Indian or Alaska Native,5,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,"race/ethnicity, customized",American Indian or Alaska Native,40,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,"race/ethnicity, customized",American Indian or Alaska Native,47,B5,Total
0,2,"race/ethnicity, customized",Asian,20,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,"race/ethnicity, customized",Asian,25,B2,Part A: Remdesivir for 10 Days
0,2,"race/ethnicity, customized",Asian,88,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,"race/ethnicity, customized",Asian,313,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,"race/ethnicity, customized",Asian,446,B5,Total
0,2,"race/ethnicity, customized",Black,21,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,"race/ethnicity, customized",Black,23,B2,Part A: Remdesivir for 10 Days
0,2,"race/ethnicity, customized",Black,149,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,"race/ethnicity, customized",Black,611,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,"race/ethnicity, customized",Black,804,B5,Total
0,2,"race/ethnicity, customized",Native Hawaiian or Pacific Islander,1,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,"race/ethnicity, customized",Native Hawaiian or Pacific Islander,0,B2,Part A: Remdesivir for 10 Days
0,2,"race/ethnicity, customized",Native Hawaiian or Pacific Islander,11,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,"race/ethnicity, customized",Native Hawaiian or Pacific Islander,29,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,"race/ethnicity, customized",Native Hawaiian or Pacific Islander,41,B5,Total
0,2,"race/ethnicity, customized",White,142,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,"race/ethnicity, customized",White,134,B2,Part A: Remdesivir for 10 Days
0,2,"race/ethnicity, customized",White,376,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,"race/ethnicity, customized",White,1915,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,"race/ethnicity, customized",White,2567,B5,Total
0,2,"race/ethnicity, customized",Not Permitted,0,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,"race/ethnicity, customized",Not Permitted,5,B2,Part A: Remdesivir for 10 Days
0,2,"race/ethnicity, customized",Not Permitted,56,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,"race/ethnicity, customized",Not Permitted,179,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,"race/ethnicity, customized",Not Permitted,240,B5,Total
0,2,"race/ethnicity, customized",Other,14,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,"race/ethnicity, customized",Other,10,B2,Part A: Remdesivir for 10 Days
0,2,"race/ethnicity, customized",Other,159,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,"race/ethnicity, customized",Other,510,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,"race/ethnicity, customized",Other,693,B5,Total
0,2,"race/ethnicity, customized",Hispanic or Latino,47,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,"race/ethnicity, customized",Hispanic or Latino,38,B2,Part A: Remdesivir for 10 Days
0,2,"race/ethnicity, customized",Hispanic or Latino,328,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,"race/ethnicity, customized",Hispanic or Latino,1341,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,"race/ethnicity, customized",Hispanic or Latino,1754,B5,Total
0,2,"race/ethnicity, customized",Not Hispanic or Latino,152,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,"race/ethnicity, customized",Not Hispanic or Latino,150,B2,Part A: Remdesivir for 10 Days
0,2,"race/ethnicity, customized",Not Hispanic or Latino,478,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,"race/ethnicity, customized",Not Hispanic or Latino,2123,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,"race/ethnicity, customized",Not Hispanic or Latino,2903,B5,Total
0,2,"race/ethnicity, customized",Not Permitted,1,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,"race/ethnicity, customized",Not Permitted,9,B2,Part A: Remdesivir for 10 Days
0,2,"race/ethnicity, customized",Not Permitted,37,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,"race/ethnicity, customized",Not Permitted,129,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,"race/ethnicity, customized",Not Permitted,176,B5,Total
0,2,"race/ethnicity, customized",Missing,0,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,"race/ethnicity, customized",Missing,0,B2,Part A: Remdesivir for 10 Days
0,2,"race/ethnicity, customized",Missing,1,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,"race/ethnicity, customized",Missing,4,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,"race/ethnicity, customized",Missing,5,B5,Total
0,2,enrollment region,United States,118,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,enrollment region,United States,111,B2,Part A: Remdesivir for 10 Days
0,2,enrollment region,United States,722,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,enrollment region,United States,2927,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,enrollment region,United States,3878,B5,Total
0,2,enrollment region,Spain,31,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,enrollment region,Spain,30,B2,Part A: Remdesivir for 10 Days
0,2,enrollment region,Spain,27,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,enrollment region,Spain,134,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,enrollment region,Spain,222,B5,Total
0,2,enrollment region,Italy,39,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,enrollment region,Italy,38,B2,Part A: Remdesivir for 10 Days
0,2,enrollment region,Italy,16,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,enrollment region,Italy,108,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,enrollment region,Italy,201,B5,Total
0,2,enrollment region,United Kingdom,0,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,enrollment region,United Kingdom,0,B2,Part A: Remdesivir for 10 Days
0,2,enrollment region,United Kingdom,33,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,enrollment region,United Kingdom,144,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,enrollment region,United Kingdom,177,B5,Total
0,2,enrollment region,Sweden,0,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,enrollment region,Sweden,0,B2,Part A: Remdesivir for 10 Days
0,2,enrollment region,Sweden,5,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,enrollment region,Sweden,83,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,enrollment region,Sweden,88,B5,Total
0,2,enrollment region,Singapore,1,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,enrollment region,Singapore,8,B2,Part A: Remdesivir for 10 Days
0,2,enrollment region,Singapore,7,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,enrollment region,Singapore,44,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,enrollment region,Singapore,60,B5,Total
0,2,enrollment region,Switzerland,0,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,enrollment region,Switzerland,0,B2,Part A: Remdesivir for 10 Days
0,2,enrollment region,Switzerland,13,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,enrollment region,Switzerland,44,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,enrollment region,Switzerland,57,B5,Total
0,2,enrollment region,Netherlands,0,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,enrollment region,Netherlands,0,B2,Part A: Remdesivir for 10 Days
0,2,enrollment region,Netherlands,2,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,enrollment region,Netherlands,45,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,enrollment region,Netherlands,47,B5,Total
0,2,enrollment region,Germany,3,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,enrollment region,Germany,1,B2,Part A: Remdesivir for 10 Days
0,2,enrollment region,Germany,12,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,enrollment region,Germany,27,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,enrollment region,Germany,43,B5,Total
0,2,enrollment region,France,0,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,enrollment region,France,0,B2,Part A: Remdesivir for 10 Days
0,2,enrollment region,France,2,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,enrollment region,France,25,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,enrollment region,France,27,B5,Total
0,2,enrollment region,South Korea,6,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,enrollment region,South Korea,6,B2,Part A: Remdesivir for 10 Days
0,2,enrollment region,South Korea,0,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,enrollment region,South Korea,10,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,enrollment region,South Korea,22,B5,Total
0,2,enrollment region,Hong Kong,2,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,enrollment region,Hong Kong,2,B2,Part A: Remdesivir for 10 Days
0,2,enrollment region,Hong Kong,2,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,enrollment region,Hong Kong,0,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,enrollment region,Hong Kong,6,B5,Total
0,2,enrollment region,Japan,0,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,enrollment region,Japan,0,B2,Part A: Remdesivir for 10 Days
0,2,enrollment region,Japan,1,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,enrollment region,Japan,4,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,enrollment region,Japan,5,B5,Total
0,2,enrollment region,Taiwan,0,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,enrollment region,Taiwan,1,B2,Part A: Remdesivir for 10 Days
0,2,enrollment region,Taiwan,2,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,enrollment region,Taiwan,2,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,enrollment region,Taiwan,5,B5,Total
0,2,clinical status (7-point ordinal scale),Score: 1,0,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,clinical status (7-point ordinal scale),Score: 1,0,B2,Part A: Remdesivir for 10 Days
0,2,clinical status (7-point ordinal scale),Score: 1,0,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,clinical status (7-point ordinal scale),Score: 1,0,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,clinical status (7-point ordinal scale),Score: 1,0,B5,Total
0,2,clinical status (7-point ordinal scale),Score: 2,4,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,clinical status (7-point ordinal scale),Score: 2,9,B2,Part A: Remdesivir for 10 Days
0,2,clinical status (7-point ordinal scale),Score: 2,844,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,clinical status (7-point ordinal scale),Score: 2,0,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,clinical status (7-point ordinal scale),Score: 2,857,B5,Total
0,2,clinical status (7-point ordinal scale),Score: 3,49,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,clinical status (7-point ordinal scale),Score: 3,59,B2,Part A: Remdesivir for 10 Days
0,2,clinical status (7-point ordinal scale),Score: 3,0,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,clinical status (7-point ordinal scale),Score: 3,1069,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,clinical status (7-point ordinal scale),Score: 3,1177,B5,Total
0,2,clinical status (7-point ordinal scale),Score: 4,113,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,clinical status (7-point ordinal scale),Score: 4,108,B2,Part A: Remdesivir for 10 Days
0,2,clinical status (7-point ordinal scale),Score: 4,0,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,clinical status (7-point ordinal scale),Score: 4,2214,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,clinical status (7-point ordinal scale),Score: 4,2435,B5,Total
0,2,clinical status (7-point ordinal scale),Score: 5,34,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,clinical status (7-point ordinal scale),Score: 5,21,B2,Part A: Remdesivir for 10 Days
0,2,clinical status (7-point ordinal scale),Score: 5,0,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,clinical status (7-point ordinal scale),Score: 5,314,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,clinical status (7-point ordinal scale),Score: 5,369,B5,Total
0,2,clinical status (7-point ordinal scale),Score: 6,0,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,clinical status (7-point ordinal scale),Score: 6,0,B2,Part A: Remdesivir for 10 Days
0,2,clinical status (7-point ordinal scale),Score: 6,0,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,clinical status (7-point ordinal scale),Score: 6,0,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,clinical status (7-point ordinal scale),Score: 6,0,B5,Total
0,2,clinical status (7-point ordinal scale),Score: 7,0,B1,Part A: Remdesivir (RDV) for 5 Days
0,2,clinical status (7-point ordinal scale),Score: 7,0,B2,Part A: Remdesivir for 10 Days
0,2,clinical status (7-point ordinal scale),Score: 7,0,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
0,2,clinical status (7-point ordinal scale),Score: 7,0,B4,Part B: Remdesivir for 10 Days (Extension Group)
0,2,clinical status (7-point ordinal scale),Score: 7,0,B5,Total
0,3,milestone,STARTED,83,P1,Exposed to Methylprednisolone
0,3,milestone,STARTED,90,P2,Non-exposed to Methylprednisolone
0,3,milestone,COMPLETED,83,P1,Exposed to Methylprednisolone
0,3,milestone,COMPLETED,90,P2,Non-exposed to Methylprednisolone
0,3,milestone,NOT COMPLETED,0,P1,Exposed to Methylprednisolone
0,3,milestone,NOT COMPLETED,0,P2,Non-exposed to Methylprednisolone
0,3,age,<=18 years,0,B1,Exposed to Methylprednisolone
0,3,age,<=18 years,0,B2,Non-exposed to Methylprednisolone
0,3,age,<=18 years,0,B3,Total
0,3,age,Between 18 and 65 years,35,B1,Exposed to Methylprednisolone
0,3,age,Between 18 and 65 years,34,B2,Non-exposed to Methylprednisolone
0,3,age,Between 18 and 65 years,69,B3,Total
0,3,age,>=65 years,48,B1,Exposed to Methylprednisolone
0,3,age,>=65 years,56,B2,Non-exposed to Methylprednisolone
0,3,age,>=65 years,104,B3,Total
0,3,"sex: female, male",Female,29,B1,Exposed to Methylprednisolone
0,3,"sex: female, male",Female,24,B2,Non-exposed to Methylprednisolone
0,3,"sex: female, male",Female,53,B3,Total
0,3,"sex: female, male",Male,54,B1,Exposed to Methylprednisolone
0,3,"sex: female, male",Male,66,B2,Non-exposed to Methylprednisolone
0,3,"sex: female, male",Male,120,B3,Total
0,3,enrollment region,Italy,83,B1,Exposed to Methylprednisolone
0,3,enrollment region,Italy,90,B2,Non-exposed to Methylprednisolone
0,3,enrollment region,Italy,173,B3,Total
0,4,milestone,STARTED,17,P1,Cohort 1 HCQ
0,4,milestone,STARTED,17,P2,Cohort 1 Placebo
0,4,milestone,STARTED,4,P3,Cohort 2 HCQ High Dose
0,4,milestone,STARTED,3,P4,Cohort 2 HCQ Low Dose
0,4,milestone,STARTED,66,P5,Cohort 3 HCQ
0,4,milestone,STARTED,66,P6,Cohort 3 Placebo
0,4,milestone,COMPLETED,16,P1,Cohort 1 HCQ
0,4,milestone,COMPLETED,13,P2,Cohort 1 Placebo
0,4,milestone,COMPLETED,3,P3,Cohort 2 HCQ High Dose
0,4,milestone,COMPLETED,2,P4,Cohort 2 HCQ Low Dose
0,4,milestone,COMPLETED,64,P5,Cohort 3 HCQ
0,4,milestone,COMPLETED,61,P6,Cohort 3 Placebo
0,4,milestone,NOT COMPLETED,1,P1,Cohort 1 HCQ
0,4,milestone,NOT COMPLETED,4,P2,Cohort 1 Placebo
0,4,milestone,NOT COMPLETED,1,P3,Cohort 2 HCQ High Dose
0,4,milestone,NOT COMPLETED,1,P4,Cohort 2 HCQ Low Dose
0,4,milestone,NOT COMPLETED,2,P5,Cohort 3 HCQ
0,4,milestone,NOT COMPLETED,5,P6,Cohort 3 Placebo
0,4,withdrawal reason,Withdrawal by Subject,1,P1,Cohort 1 HCQ
0,4,withdrawal reason,Withdrawal by Subject,4,P2,Cohort 1 Placebo
0,4,withdrawal reason,Withdrawal by Subject,1,P3,Cohort 2 HCQ High Dose
0,4,withdrawal reason,Withdrawal by Subject,1,P4,Cohort 2 HCQ Low Dose
0,4,withdrawal reason,Withdrawal by Subject,1,P5,Cohort 3 HCQ
0,4,withdrawal reason,Withdrawal by Subject,1,P6,Cohort 3 Placebo
0,4,withdrawal reason,early termination of study,0,P1,Cohort 1 HCQ
0,4,withdrawal reason,early termination of study,0,P2,Cohort 1 Placebo
0,4,withdrawal reason,early termination of study,0,P3,Cohort 2 HCQ High Dose
0,4,withdrawal reason,early termination of study,0,P4,Cohort 2 HCQ Low Dose
0,4,withdrawal reason,early termination of study,1,P5,Cohort 3 HCQ
0,4,withdrawal reason,early termination of study,2,P6,Cohort 3 Placebo
0,4,withdrawal reason,positive SARS-COV2 PCR at baseline,0,P1,Cohort 1 HCQ
0,4,withdrawal reason,positive SARS-COV2 PCR at baseline,0,P2,Cohort 1 Placebo
0,4,withdrawal reason,positive SARS-COV2 PCR at baseline,0,P3,Cohort 2 HCQ High Dose
0,4,withdrawal reason,positive SARS-COV2 PCR at baseline,0,P4,Cohort 2 HCQ Low Dose
0,4,withdrawal reason,positive SARS-COV2 PCR at baseline,0,P5,Cohort 3 HCQ
0,4,withdrawal reason,positive SARS-COV2 PCR at baseline,2,P6,Cohort 3 Placebo
0,4,"sex: female, male",Female,12,B1,Cohort 1 HCQ
0,4,"sex: female, male",Female,9,B2,Cohort 1 Placebo
0,4,"sex: female, male",Female,2,B3,Cohort 2 HCQ High Dose
0,4,"sex: female, male",Female,3,B4,Cohort 2 HCQ Low Dose
0,4,"sex: female, male",Female,54,B5,Cohort 3 HCQ
0,4,"sex: female, male",Female,33,B6,Cohort 3 Placebo
0,4,"sex: female, male",Female,113,B7,Total
0,4,"sex: female, male",Male,5,B1,Cohort 1 HCQ
0,4,"sex: female, male",Male,8,B2,Cohort 1 Placebo
0,4,"sex: female, male",Male,2,B3,Cohort 2 HCQ High Dose
0,4,"sex: female, male",Male,0,B4,Cohort 2 HCQ Low Dose
0,4,"sex: female, male",Male,12,B5,Cohort 3 HCQ
0,4,"sex: female, male",Male,33,B6,Cohort 3 Placebo
0,4,"sex: female, male",Male,60,B7,Total
0,4,race (nih/omb),American Indian or Alaska Native,0,B1,Cohort 1 HCQ
0,4,race (nih/omb),American Indian or Alaska Native,0,B2,Cohort 1 Placebo
0,4,race (nih/omb),American Indian or Alaska Native,0,B3,Cohort 2 HCQ High Dose
0,4,race (nih/omb),American Indian or Alaska Native,0,B4,Cohort 2 HCQ Low Dose
0,4,race (nih/omb),American Indian or Alaska Native,0,B5,Cohort 3 HCQ
0,4,race (nih/omb),American Indian or Alaska Native,0,B6,Cohort 3 Placebo
0,4,race (nih/omb),American Indian or Alaska Native,0,B7,Total
0,4,race (nih/omb),Asian,0,B1,Cohort 1 HCQ
0,4,race (nih/omb),Asian,0,B2,Cohort 1 Placebo
0,4,race (nih/omb),Asian,0,B3,Cohort 2 HCQ High Dose
0,4,race (nih/omb),Asian,0,B4,Cohort 2 HCQ Low Dose
0,4,race (nih/omb),Asian,7,B5,Cohort 3 HCQ
0,4,race (nih/omb),Asian,7,B6,Cohort 3 Placebo
0,4,race (nih/omb),Asian,14,B7,Total
0,4,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B1,Cohort 1 HCQ
0,4,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B2,Cohort 1 Placebo
0,4,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B3,Cohort 2 HCQ High Dose
0,4,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B4,Cohort 2 HCQ Low Dose
0,4,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B5,Cohort 3 HCQ
0,4,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B6,Cohort 3 Placebo
0,4,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B7,Total
0,4,race (nih/omb),Black or African American,8,B1,Cohort 1 HCQ
0,4,race (nih/omb),Black or African American,11,B2,Cohort 1 Placebo
0,4,race (nih/omb),Black or African American,3,B3,Cohort 2 HCQ High Dose
0,4,race (nih/omb),Black or African American,3,B4,Cohort 2 HCQ Low Dose
0,4,race (nih/omb),Black or African American,3,B5,Cohort 3 HCQ
0,4,race (nih/omb),Black or African American,1,B6,Cohort 3 Placebo
0,4,race (nih/omb),Black or African American,29,B7,Total
0,4,race (nih/omb),White,6,B1,Cohort 1 HCQ
0,4,race (nih/omb),White,3,B2,Cohort 1 Placebo
0,4,race (nih/omb),White,1,B3,Cohort 2 HCQ High Dose
0,4,race (nih/omb),White,0,B4,Cohort 2 HCQ Low Dose
0,4,race (nih/omb),White,55,B5,Cohort 3 HCQ
0,4,race (nih/omb),White,56,B6,Cohort 3 Placebo
0,4,race (nih/omb),White,121,B7,Total
0,4,race (nih/omb),More than one race,0,B1,Cohort 1 HCQ
0,4,race (nih/omb),More than one race,0,B2,Cohort 1 Placebo
0,4,race (nih/omb),More than one race,0,B3,Cohort 2 HCQ High Dose
0,4,race (nih/omb),More than one race,0,B4,Cohort 2 HCQ Low Dose
0,4,race (nih/omb),More than one race,1,B5,Cohort 3 HCQ
0,4,race (nih/omb),More than one race,2,B6,Cohort 3 Placebo
0,4,race (nih/omb),More than one race,3,B7,Total
0,4,race (nih/omb),Unknown or Not Reported,3,B1,Cohort 1 HCQ
0,4,race (nih/omb),Unknown or Not Reported,3,B2,Cohort 1 Placebo
0,4,race (nih/omb),Unknown or Not Reported,0,B3,Cohort 2 HCQ High Dose
0,4,race (nih/omb),Unknown or Not Reported,0,B4,Cohort 2 HCQ Low Dose
0,4,race (nih/omb),Unknown or Not Reported,0,B5,Cohort 3 HCQ
0,4,race (nih/omb),Unknown or Not Reported,0,B6,Cohort 3 Placebo
0,4,race (nih/omb),Unknown or Not Reported,6,B7,Total
0,5,milestone,STARTED,2,P1,GO2 PEEP MOUTHPIECE
0,5,milestone,COMPLETED,2,P1,GO2 PEEP MOUTHPIECE
0,5,milestone,NOT COMPLETED,0,P1,GO2 PEEP MOUTHPIECE
0,5,"sex: female, male",Female,0,B1,GO2 PEEP MOUTHPIECE
0,5,"sex: female, male",Male,2,B1,GO2 PEEP MOUTHPIECE
0,5,ethnicity (nih/omb),Hispanic or Latino,1,B1,GO2 PEEP MOUTHPIECE
0,5,ethnicity (nih/omb),Not Hispanic or Latino,1,B1,GO2 PEEP MOUTHPIECE
0,5,ethnicity (nih/omb),Unknown or Not Reported,0,B1,GO2 PEEP MOUTHPIECE
0,5,race (nih/omb),American Indian or Alaska Native,0,B1,GO2 PEEP MOUTHPIECE
0,5,race (nih/omb),Asian,0,B1,GO2 PEEP MOUTHPIECE
0,5,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B1,GO2 PEEP MOUTHPIECE
0,5,race (nih/omb),Black or African American,0,B1,GO2 PEEP MOUTHPIECE
0,5,race (nih/omb),White,1,B1,GO2 PEEP MOUTHPIECE
0,5,race (nih/omb),More than one race,0,B1,GO2 PEEP MOUTHPIECE
0,5,race (nih/omb),Unknown or Not Reported,1,B1,GO2 PEEP MOUTHPIECE
0,5,enrollment region,United States,2,B1,GO2 PEEP MOUTHPIECE
0,6,milestone,STARTED,242,P1,Hydroxychloroquine
0,6,milestone,STARTED,237,P2,Placebo
0,6,milestone,COMPLETED,242,P1,Hydroxychloroquine
0,6,milestone,COMPLETED,237,P2,Placebo
0,6,milestone,NOT COMPLETED,0,P1,Hydroxychloroquine
0,6,milestone,NOT COMPLETED,0,P2,Placebo
0,6,"sex: female, male",Female,107,B1,Hydroxychloroquine
0,6,"sex: female, male",Female,105,B2,Placebo
0,6,"sex: female, male",Female,212,B3,Total
0,6,"sex: female, male",Male,135,B1,Hydroxychloroquine
0,6,"sex: female, male",Male,132,B2,Placebo
0,6,"sex: female, male",Male,267,B3,Total
0,6,covid outcomes scale category at randomization,"2: Hospitalized, receiving ECMO or invasive mechanical ventilation",13,B1,Hydroxychloroquine
0,6,covid outcomes scale category at randomization,"2: Hospitalized, receiving ECMO or invasive mechanical ventilation",19,B2,Placebo
0,6,covid outcomes scale category at randomization,"2: Hospitalized, receiving ECMO or invasive mechanical ventilation",32,B3,Total
0,6,covid outcomes scale category at randomization,"3: Hospitalized, receiving noninvasive ventilation or nasal high flow oxygen",28,B1,Hydroxychloroquine
0,6,covid outcomes scale category at randomization,"3: Hospitalized, receiving noninvasive ventilation or nasal high flow oxygen",27,B2,Placebo
0,6,covid outcomes scale category at randomization,"3: Hospitalized, receiving noninvasive ventilation or nasal high flow oxygen",55,B3,Total
0,6,covid outcomes scale category at randomization,"4: Hospitalized, receiving supplemental oxygen without positive pressure or high flow",116,B1,Hydroxychloroquine
0,6,covid outcomes scale category at randomization,"4: Hospitalized, receiving supplemental oxygen without positive pressure or high flow",108,B2,Placebo
0,6,covid outcomes scale category at randomization,"4: Hospitalized, receiving supplemental oxygen without positive pressure or high flow",224,B3,Total
0,6,covid outcomes scale category at randomization,"5: Hospitalized, not receiving supplemental oxygen",85,B1,Hydroxychloroquine
0,6,covid outcomes scale category at randomization,"5: Hospitalized, not receiving supplemental oxygen",83,B2,Placebo
0,6,covid outcomes scale category at randomization,"5: Hospitalized, not receiving supplemental oxygen",168,B3,Total
0,7,milestone,STARTED,16,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT)
0,7,milestone,COMPLETED,16,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT)
0,7,milestone,NOT COMPLETED,0,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT)
0,7,"sex: female, male",Female,5,B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT)
0,7,"sex: female, male",Male,11,B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT)
0,7,enrollment region,Iraq,16,B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT)
0,8,milestone,STARTED,48,P1,COVID-19 Patients Treated With Convalescent Plasma
0,8,milestone,COMPLETED,40,P1,COVID-19 Patients Treated With Convalescent Plasma
0,8,milestone,NOT COMPLETED,8,P1,COVID-19 Patients Treated With Convalescent Plasma
0,8,withdrawal reason,Adverse Event,1,P1,COVID-19 Patients Treated With Convalescent Plasma
0,8,withdrawal reason,received inadequate amount of antibodies,7,P1,COVID-19 Patients Treated With Convalescent Plasma
0,8,age,<=18 years,0,B1,COVID-19 Patients Treated With Convalescent Plasma
0,8,age,Between 18 and 65 years,24,B1,COVID-19 Patients Treated With Convalescent Plasma
0,8,age,>=65 years,24,B1,COVID-19 Patients Treated With Convalescent Plasma
0,8,"sex: female, male",Female,21,B1,COVID-19 Patients Treated With Convalescent Plasma
0,8,"sex: female, male",Male,27,B1,COVID-19 Patients Treated With Convalescent Plasma
0,8,ethnicity (nih/omb),Hispanic or Latino,12,B1,COVID-19 Patients Treated With Convalescent Plasma
0,8,ethnicity (nih/omb),Not Hispanic or Latino,34,B1,COVID-19 Patients Treated With Convalescent Plasma
0,8,ethnicity (nih/omb),Unknown or Not Reported,2,B1,COVID-19 Patients Treated With Convalescent Plasma
0,8,race (nih/omb),American Indian or Alaska Native,0,B1,COVID-19 Patients Treated With Convalescent Plasma
0,8,race (nih/omb),Asian,0,B1,COVID-19 Patients Treated With Convalescent Plasma
0,8,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B1,COVID-19 Patients Treated With Convalescent Plasma
0,8,race (nih/omb),Black or African American,16,B1,COVID-19 Patients Treated With Convalescent Plasma
0,8,race (nih/omb),White,17,B1,COVID-19 Patients Treated With Convalescent Plasma
0,8,race (nih/omb),More than one race,12,B1,COVID-19 Patients Treated With Convalescent Plasma
0,8,race (nih/omb),Unknown or Not Reported,3,B1,COVID-19 Patients Treated With Convalescent Plasma
0,8,enrollment region,United States,48,B1,COVID-19 Patients Treated With Convalescent Plasma
0,9,milestone,STARTED,9,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)
0,9,milestone,STARTED,11,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin
0,9,milestone,COMPLETED,7,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)
0,9,milestone,COMPLETED,9,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin
0,9,milestone,NOT COMPLETED,2,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)
0,9,milestone,NOT COMPLETED,2,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin
0,9,withdrawal reason,Did not initiate study treatment,2,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)
0,9,withdrawal reason,Did not initiate study treatment,2,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin
0,9,"sex: female, male",Female,7,B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)
0,9,"sex: female, male",Female,4,B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin
0,9,"sex: female, male",Female,11,B3,Total
0,9,"sex: female, male",Male,0,B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)
0,9,"sex: female, male",Male,5,B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin
0,9,"sex: female, male",Male,5,B3,Total
0,9,ethnicity (nih/omb),Hispanic or Latino,2,B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)
0,9,ethnicity (nih/omb),Hispanic or Latino,2,B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin
0,9,ethnicity (nih/omb),Hispanic or Latino,4,B3,Total
0,9,ethnicity (nih/omb),Not Hispanic or Latino,5,B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)
0,9,ethnicity (nih/omb),Not Hispanic or Latino,6,B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin
0,9,ethnicity (nih/omb),Not Hispanic or Latino,11,B3,Total
0,9,ethnicity (nih/omb),Unknown or Not Reported,0,B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)
0,9,ethnicity (nih/omb),Unknown or Not Reported,1,B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin
0,9,ethnicity (nih/omb),Unknown or Not Reported,1,B3,Total
0,9,race (nih/omb),American Indian or Alaska Native,0,B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)
0,9,race (nih/omb),American Indian or Alaska Native,0,B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin
0,9,race (nih/omb),American Indian or Alaska Native,0,B3,Total
0,9,race (nih/omb),Asian,0,B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)
0,9,race (nih/omb),Asian,0,B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin
0,9,race (nih/omb),Asian,0,B3,Total
0,9,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)
0,9,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin
0,9,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B3,Total
0,9,race (nih/omb),Black or African American,1,B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)
0,9,race (nih/omb),Black or African American,0,B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin
0,9,race (nih/omb),Black or African American,1,B3,Total
0,9,race (nih/omb),White,6,B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)
0,9,race (nih/omb),White,8,B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin
0,9,race (nih/omb),White,14,B3,Total
0,9,race (nih/omb),More than one race,0,B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)
0,9,race (nih/omb),More than one race,0,B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin
0,9,race (nih/omb),More than one race,0,B3,Total
0,9,race (nih/omb),Unknown or Not Reported,0,B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)
0,9,race (nih/omb),Unknown or Not Reported,1,B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin
0,9,race (nih/omb),Unknown or Not Reported,1,B3,Total
0,9,enrollment region,United States,7,B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)
0,9,enrollment region,United States,9,B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin
0,9,enrollment region,United States,16,B3,Total
0,10,milestone,STARTED,7,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo
0,10,milestone,STARTED,7,P2,Arm 2: Hydroxychloroquine + Azithromycin
0,10,milestone,STARTED,5,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo
0,10,milestone,COMPLETED,3,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo
0,10,milestone,COMPLETED,6,P2,Arm 2: Hydroxychloroquine + Azithromycin
0,10,milestone,COMPLETED,2,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo
0,10,milestone,NOT COMPLETED,4,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo
0,10,milestone,NOT COMPLETED,1,P2,Arm 2: Hydroxychloroquine + Azithromycin
0,10,milestone,NOT COMPLETED,3,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo
0,10,withdrawal reason,Withdrawal by Subject,0,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo
0,10,withdrawal reason,Withdrawal by Subject,1,P2,Arm 2: Hydroxychloroquine + Azithromycin
0,10,withdrawal reason,Withdrawal by Subject,1,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo
0,10,withdrawal reason,Adverse Event,1,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo
0,10,withdrawal reason,Adverse Event,0,P2,Arm 2: Hydroxychloroquine + Azithromycin
0,10,withdrawal reason,Adverse Event,1,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo
0,10,withdrawal reason,Physician Decision,2,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo
0,10,withdrawal reason,Physician Decision,0,P2,Arm 2: Hydroxychloroquine + Azithromycin
0,10,withdrawal reason,Physician Decision,1,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo
0,10,withdrawal reason,Protocol Violation,1,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo
0,10,withdrawal reason,Protocol Violation,0,P2,Arm 2: Hydroxychloroquine + Azithromycin
0,10,withdrawal reason,Protocol Violation,0,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo
0,10,age,<=18 years,0,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo
0,10,age,<=18 years,0,B2,Arm 2: Hydroxychloroquine + Azithromycin
0,10,age,<=18 years,0,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo
0,10,age,<=18 years,0,B4,Total
0,10,age,Between 18 and 65 years,7,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo
0,10,age,Between 18 and 65 years,4,B2,Arm 2: Hydroxychloroquine + Azithromycin
0,10,age,Between 18 and 65 years,5,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo
0,10,age,Between 18 and 65 years,16,B4,Total
0,10,age,>=65 years,0,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo
0,10,age,>=65 years,3,B2,Arm 2: Hydroxychloroquine + Azithromycin
0,10,age,>=65 years,0,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo
0,10,age,>=65 years,3,B4,Total
0,10,"sex: female, male",Female,3,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo
0,10,"sex: female, male",Female,1,B2,Arm 2: Hydroxychloroquine + Azithromycin
0,10,"sex: female, male",Female,3,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo
0,10,"sex: female, male",Female,7,B4,Total
0,10,"sex: female, male",Male,4,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo
0,10,"sex: female, male",Male,6,B2,Arm 2: Hydroxychloroquine + Azithromycin
0,10,"sex: female, male",Male,2,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo
0,10,"sex: female, male",Male,12,B4,Total
0,11,milestone,STARTED,5712,P1,Pregnant Women
0,11,milestone,STARTED,1182,P2,Post-partum Women
0,11,milestone,COMPLETED,5712,P1,Pregnant Women
0,11,milestone,COMPLETED,1182,P2,Post-partum Women
0,11,milestone,NOT COMPLETED,0,P1,Pregnant Women
0,11,milestone,NOT COMPLETED,0,P2,Post-partum Women
0,11,"sex: female, male",Female,5712,B1,Pregnant Women
0,11,"sex: female, male",Female,1182,B2,Post-partum Women
0,11,"sex: female, male",Female,6894,B3,Total
0,11,"sex: female, male",Male,0,B1,Pregnant Women
0,11,"sex: female, male",Male,0,B2,Post-partum Women
0,11,"sex: female, male",Male,0,B3,Total
0,11,ethnicity (nih/omb),Hispanic or Latino,1288,B1,Pregnant Women
0,11,ethnicity (nih/omb),Hispanic or Latino,131,B2,Post-partum Women
0,11,ethnicity (nih/omb),Hispanic or Latino,1419,B3,Total
0,11,ethnicity (nih/omb),Not Hispanic or Latino,4424,B1,Pregnant Women
0,11,ethnicity (nih/omb),Not Hispanic or Latino,1051,B2,Post-partum Women
0,11,ethnicity (nih/omb),Not Hispanic or Latino,5475,B3,Total
0,11,ethnicity (nih/omb),Unknown or Not Reported,0,B1,Pregnant Women
0,11,ethnicity (nih/omb),Unknown or Not Reported,0,B2,Post-partum Women
0,11,ethnicity (nih/omb),Unknown or Not Reported,0,B3,Total
0,12,milestone,STARTED,12,P1,Ivermectin
0,12,milestone,STARTED,12,P2,Placebo
0,12,milestone,COMPLETED,12,P1,Ivermectin
0,12,milestone,COMPLETED,12,P2,Placebo
0,12,milestone,NOT COMPLETED,0,P1,Ivermectin
0,12,milestone,NOT COMPLETED,0,P2,Placebo
0,12,"sex: female, male",Female,5,B1,Ivermectin
0,12,"sex: female, male",Female,7,B2,Placebo
0,12,"sex: female, male",Female,12,B3,Total
0,12,"sex: female, male",Male,7,B1,Ivermectin
0,12,"sex: female, male",Male,5,B2,Placebo
0,12,"sex: female, male",Male,12,B3,Total
0,13,milestone,STARTED,15,P1,FAVIRA Then AVIGAN
0,13,milestone,STARTED,15,P2,AVIGAN Then FAVIRA
0,13,milestone,COMPLETED,14,P1,FAVIRA Then AVIGAN
0,13,milestone,COMPLETED,11,P2,AVIGAN Then FAVIRA
0,13,milestone,NOT COMPLETED,1,P1,FAVIRA Then AVIGAN
0,13,milestone,NOT COMPLETED,4,P2,AVIGAN Then FAVIRA
0,13,withdrawal reason,Withdrawal by Subject,1,P1,FAVIRA Then AVIGAN
0,13,withdrawal reason,Withdrawal by Subject,4,P2,AVIGAN Then FAVIRA
0,13,"sex: female, male",Female,0,B1,FAVIRA Then AVIGAN
0,13,"sex: female, male",Female,0,B2,AVIGAN Then FAVIRA
0,13,"sex: female, male",Female,0,B3,Total
0,13,"sex: female, male",Male,15,B1,FAVIRA Then AVIGAN
0,13,"sex: female, male",Male,15,B2,AVIGAN Then FAVIRA
0,13,"sex: female, male",Male,30,B3,Total
0,14,milestone,STARTED,15,P1,Experimental: FAVICOVIR Then AVIGAN
0,14,milestone,STARTED,15,P2,AVIGAN Then FAVICOVIR
0,14,milestone,COMPLETED,15,P1,Experimental: FAVICOVIR Then AVIGAN
0,14,milestone,COMPLETED,14,P2,AVIGAN Then FAVICOVIR
0,14,milestone,NOT COMPLETED,0,P1,Experimental: FAVICOVIR Then AVIGAN
0,14,milestone,NOT COMPLETED,1,P2,AVIGAN Then FAVICOVIR
0,14,withdrawal reason,Withdrawal by Subject,0,P1,Experimental: FAVICOVIR Then AVIGAN
0,14,withdrawal reason,Withdrawal by Subject,1,P2,AVIGAN Then FAVICOVIR
0,14,"sex: female, male",Female,0,B1,FAVICOVIR Then AVIGAN
0,14,"sex: female, male",Female,0,B2,AVIGAN Then FAVICOVIR
0,14,"sex: female, male",Female,0,B3,Total
0,14,"sex: female, male",Male,15,B1,FAVICOVIR Then AVIGAN
0,14,"sex: female, male",Male,15,B2,AVIGAN Then FAVICOVIR
0,14,"sex: female, male",Male,30,B3,Total
0,15,milestone,STARTED,5,P1,Povidone-iodine
0,15,milestone,STARTED,5,P2,Essential Oils
0,15,milestone,STARTED,5,P3,Tap Water
0,15,milestone,STARTED,5,P4,Control
0,15,milestone,COMPLETED,5,P1,Povidone-iodine
0,15,milestone,COMPLETED,5,P2,Essential Oils
0,15,milestone,COMPLETED,5,P3,Tap Water
0,15,milestone,COMPLETED,5,P4,Control
0,15,milestone,NOT COMPLETED,0,P1,Povidone-iodine
0,15,milestone,NOT COMPLETED,0,P2,Essential Oils
0,15,milestone,NOT COMPLETED,0,P3,Tap Water
0,15,milestone,NOT COMPLETED,0,P4,Control
0,15,age,<=18 years,0,B1,Povidone-iodine
0,15,age,<=18 years,0,B2,Essential Oils
0,15,age,<=18 years,0,B3,Tap Water
0,15,age,<=18 years,0,B4,Control
0,15,age,<=18 years,0,B5,Total
0,15,age,Between 18 and 65 years,5,B1,Povidone-iodine
0,15,age,Between 18 and 65 years,5,B2,Essential Oils
0,15,age,Between 18 and 65 years,5,B3,Tap Water
0,15,age,Between 18 and 65 years,5,B4,Control
0,15,age,Between 18 and 65 years,20,B5,Total
0,15,age,>=65 years,0,B1,Povidone-iodine
0,15,age,>=65 years,0,B2,Essential Oils
0,15,age,>=65 years,0,B3,Tap Water
0,15,age,>=65 years,0,B4,Control
0,15,age,>=65 years,0,B5,Total
0,15,"sex: female, male",Female,3,B1,Povidone-iodine
0,15,"sex: female, male",Female,1,B2,Essential Oils
0,15,"sex: female, male",Female,0,B3,Tap Water
0,15,"sex: female, male",Female,0,B4,Control
0,15,"sex: female, male",Female,4,B5,Total
0,15,"sex: female, male",Male,2,B1,Povidone-iodine
0,15,"sex: female, male",Male,4,B2,Essential Oils
0,15,"sex: female, male",Male,5,B3,Tap Water
0,15,"sex: female, male",Male,5,B4,Control
0,15,"sex: female, male",Male,16,B5,Total
0,15,race (nih/omb),American Indian or Alaska Native,0,B1,Povidone-iodine
0,15,race (nih/omb),American Indian or Alaska Native,0,B2,Essential Oils
0,15,race (nih/omb),American Indian or Alaska Native,0,B3,Tap Water
0,15,race (nih/omb),American Indian or Alaska Native,0,B4,Control
0,15,race (nih/omb),American Indian or Alaska Native,0,B5,Total
0,15,race (nih/omb),Asian,5,B1,Povidone-iodine
0,15,race (nih/omb),Asian,5,B2,Essential Oils
0,15,race (nih/omb),Asian,5,B3,Tap Water
0,15,race (nih/omb),Asian,5,B4,Control
0,15,race (nih/omb),Asian,20,B5,Total
0,15,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B1,Povidone-iodine
0,15,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B2,Essential Oils
0,15,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B3,Tap Water
0,15,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B4,Control
0,15,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B5,Total
0,15,race (nih/omb),Black or African American,0,B1,Povidone-iodine
0,15,race (nih/omb),Black or African American,0,B2,Essential Oils
0,15,race (nih/omb),Black or African American,0,B3,Tap Water
0,15,race (nih/omb),Black or African American,0,B4,Control
0,15,race (nih/omb),Black or African American,0,B5,Total
0,15,race (nih/omb),White,0,B1,Povidone-iodine
0,15,race (nih/omb),White,0,B2,Essential Oils
0,15,race (nih/omb),White,0,B3,Tap Water
0,15,race (nih/omb),White,0,B4,Control
0,15,race (nih/omb),White,0,B5,Total
0,15,race (nih/omb),More than one race,0,B1,Povidone-iodine
0,15,race (nih/omb),More than one race,0,B2,Essential Oils
0,15,race (nih/omb),More than one race,0,B3,Tap Water
0,15,race (nih/omb),More than one race,0,B4,Control
0,15,race (nih/omb),More than one race,0,B5,Total
0,15,race (nih/omb),Unknown or Not Reported,0,B1,Povidone-iodine
0,15,race (nih/omb),Unknown or Not Reported,0,B2,Essential Oils
0,15,race (nih/omb),Unknown or Not Reported,0,B3,Tap Water
0,15,race (nih/omb),Unknown or Not Reported,0,B4,Control
0,15,race (nih/omb),Unknown or Not Reported,0,B5,Total
0,15,enrollment region,Malaysia,5,B1,Povidone-iodine
0,15,enrollment region,Malaysia,5,B2,Essential Oils
0,15,enrollment region,Malaysia,5,B3,Tap Water
0,15,enrollment region,Malaysia,5,B4,Control
0,15,enrollment region,Malaysia,20,B5,Total
0,16,milestone,STARTED,228,P1,Ivermectin Group
0,16,milestone,STARTED,112,P2,Control Group
0,16,milestone,COMPLETED,203,P1,Ivermectin Group
0,16,milestone,COMPLETED,101,P2,Control Group
0,16,milestone,NOT COMPLETED,25,P1,Ivermectin Group
0,16,milestone,NOT COMPLETED,11,P2,Control Group
0,16,withdrawal reason,Lost to Follow-up,25,P1,Ivermectin Group
0,16,withdrawal reason,Lost to Follow-up,11,P2,Control Group
0,16,"sex: female, male",Female,97,B1,Ivermectin Group
0,16,"sex: female, male",Female,51,B2,Control Group
0,16,"sex: female, male",Female,148,B3,Total
0,16,"sex: female, male",Male,106,B1,Ivermectin Group
0,16,"sex: female, male",Male,50,B2,Control Group
0,16,"sex: female, male",Male,156,B3,Total
0,17,milestone,STARTED,131,P1,IVER+
0,17,milestone,STARTED,98,P2,IVER-
0,17,milestone,COMPLETED,131,P1,IVER+
0,17,milestone,COMPLETED,98,P2,IVER-
0,17,milestone,NOT COMPLETED,0,P1,IVER+
0,17,milestone,NOT COMPLETED,0,P2,IVER-
0,17,"sex: female, male",Female,70,B1,IVER+
0,17,"sex: female, male",Female,72,B2,IVER-
0,17,"sex: female, male",Female,142,B3,Total
0,17,"sex: female, male",Male,61,B1,IVER+
0,17,"sex: female, male",Male,26,B2,IVER-
0,17,"sex: female, male",Male,87,B3,Total
0,17,ethnicity (nih/omb),Hispanic or Latino,131,B1,IVER+
0,17,ethnicity (nih/omb),Hispanic or Latino,98,B2,IVER-
0,17,ethnicity (nih/omb),Hispanic or Latino,229,B3,Total
0,17,ethnicity (nih/omb),Not Hispanic or Latino,0,B1,IVER+
0,17,ethnicity (nih/omb),Not Hispanic or Latino,0,B2,IVER-
0,17,ethnicity (nih/omb),Not Hispanic or Latino,0,B3,Total
0,17,ethnicity (nih/omb),Unknown or Not Reported,0,B1,IVER+
0,17,ethnicity (nih/omb),Unknown or Not Reported,0,B2,IVER-
0,17,ethnicity (nih/omb),Unknown or Not Reported,0,B3,Total
0,17,race (nih/omb),American Indian or Alaska Native,0,B1,IVER+
0,17,race (nih/omb),American Indian or Alaska Native,0,B2,IVER-
0,17,race (nih/omb),American Indian or Alaska Native,0,B3,Total
0,17,race (nih/omb),Asian,0,B1,IVER+
0,17,race (nih/omb),Asian,0,B2,IVER-
0,17,race (nih/omb),Asian,0,B3,Total
0,17,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B1,IVER+
0,17,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B2,IVER-
0,17,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B3,Total
0,17,race (nih/omb),Black or African American,0,B1,IVER+
0,17,race (nih/omb),Black or African American,0,B2,IVER-
0,17,race (nih/omb),Black or African American,0,B3,Total
0,17,race (nih/omb),White,0,B1,IVER+
0,17,race (nih/omb),White,0,B2,IVER-
0,17,race (nih/omb),White,0,B3,Total
0,17,race (nih/omb),More than one race,131,B1,IVER+
0,17,race (nih/omb),More than one race,98,B2,IVER-
0,17,race (nih/omb),More than one race,229,B3,Total
0,17,race (nih/omb),Unknown or Not Reported,0,B1,IVER+
0,17,race (nih/omb),Unknown or Not Reported,0,B2,IVER-
0,17,race (nih/omb),Unknown or Not Reported,0,B3,Total
0,17,enrollment region,Argentina,131,B1,IVER+
0,17,enrollment region,Argentina,98,B2,IVER-
0,17,enrollment region,Argentina,229,B3,Total
0,18,milestone,STARTED,135,P1,Mild Cases
0,18,milestone,STARTED,12,P2,Moderate Cases
0,18,milestone,STARTED,20,P3,Severe Cases
0,18,milestone,COMPLETED,135,P1,Mild Cases
0,18,milestone,COMPLETED,12,P2,Moderate Cases
0,18,milestone,COMPLETED,19,P3,Severe Cases
0,18,milestone,NOT COMPLETED,0,P1,Mild Cases
0,18,milestone,NOT COMPLETED,0,P2,Moderate Cases
0,18,milestone,NOT COMPLETED,1,P3,Severe Cases
0,18,withdrawal reason,Death,0,P1,Mild Cases
0,18,withdrawal reason,Death,0,P2,Moderate Cases
0,18,withdrawal reason,Death,1,P3,Severe Cases
0,18,"sex: female, male",Female,66,B1,Mild Cases
0,18,"sex: female, male",Female,7,B2,Moderate Cases
0,18,"sex: female, male",Female,11,B3,Severe Cases
0,18,"sex: female, male",Female,84,B4,Total
0,18,"sex: female, male",Male,69,B1,Mild Cases
0,18,"sex: female, male",Male,5,B2,Moderate Cases
0,18,"sex: female, male",Male,9,B3,Severe Cases
0,18,"sex: female, male",Male,83,B4,Total
0,18,ethnicity (nih/omb),Hispanic or Latino,135,B1,Mild Cases
0,18,ethnicity (nih/omb),Hispanic or Latino,12,B2,Moderate Cases
0,18,ethnicity (nih/omb),Hispanic or Latino,20,B3,Severe Cases
0,18,ethnicity (nih/omb),Hispanic or Latino,167,B4,Total
0,18,ethnicity (nih/omb),Not Hispanic or Latino,0,B1,Mild Cases
0,18,ethnicity (nih/omb),Not Hispanic or Latino,0,B2,Moderate Cases
0,18,ethnicity (nih/omb),Not Hispanic or Latino,0,B3,Severe Cases
0,18,ethnicity (nih/omb),Not Hispanic or Latino,0,B4,Total
0,18,ethnicity (nih/omb),Unknown or Not Reported,0,B1,Mild Cases
0,18,ethnicity (nih/omb),Unknown or Not Reported,0,B2,Moderate Cases
0,18,ethnicity (nih/omb),Unknown or Not Reported,0,B3,Severe Cases
0,18,ethnicity (nih/omb),Unknown or Not Reported,0,B4,Total
0,18,race (nih/omb),American Indian or Alaska Native,0,B1,Mild Cases
0,18,race (nih/omb),American Indian or Alaska Native,0,B2,Moderate Cases
0,18,race (nih/omb),American Indian or Alaska Native,0,B3,Severe Cases
0,18,race (nih/omb),American Indian or Alaska Native,0,B4,Total
0,18,race (nih/omb),Asian,0,B1,Mild Cases
0,18,race (nih/omb),Asian,0,B2,Moderate Cases
0,18,race (nih/omb),Asian,0,B3,Severe Cases
0,18,race (nih/omb),Asian,0,B4,Total
0,18,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B1,Mild Cases
0,18,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B2,Moderate Cases
0,18,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B3,Severe Cases
0,18,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B4,Total
0,18,race (nih/omb),Black or African American,0,B1,Mild Cases
0,18,race (nih/omb),Black or African American,0,B2,Moderate Cases
0,18,race (nih/omb),Black or African American,0,B3,Severe Cases
0,18,race (nih/omb),Black or African American,0,B4,Total
0,18,race (nih/omb),White,0,B1,Mild Cases
0,18,race (nih/omb),White,0,B2,Moderate Cases
0,18,race (nih/omb),White,0,B3,Severe Cases
0,18,race (nih/omb),White,0,B4,Total
0,18,race (nih/omb),More than one race,135,B1,Mild Cases
0,18,race (nih/omb),More than one race,12,B2,Moderate Cases
0,18,race (nih/omb),More than one race,20,B3,Severe Cases
0,18,race (nih/omb),More than one race,167,B4,Total
0,18,race (nih/omb),Unknown or Not Reported,0,B1,Mild Cases
0,18,race (nih/omb),Unknown or Not Reported,0,B2,Moderate Cases
0,18,race (nih/omb),Unknown or Not Reported,0,B3,Severe Cases
0,18,race (nih/omb),Unknown or Not Reported,0,B4,Total
0,18,enrollment region,Argentina,135,B1,Mild Cases
0,18,enrollment region,Argentina,12,B2,Moderate Cases
0,18,enrollment region,Argentina,20,B3,Severe Cases
0,18,enrollment region,Argentina,167,B4,Total
0,19,milestone,STARTED,0,P1,Hydroxychloroquine Arm
0,19,milestone,STARTED,1,P2,No Intervention Arm
0,19,milestone,COMPLETED,0,P1,Hydroxychloroquine Arm
0,19,milestone,COMPLETED,0,P2,No Intervention Arm
0,19,milestone,NOT COMPLETED,0,P1,Hydroxychloroquine Arm
0,19,milestone,NOT COMPLETED,1,P2,No Intervention Arm
0,19,withdrawal reason,Study stopped by DSMB,0,P1,Hydroxychloroquine Arm
0,19,withdrawal reason,Study stopped by DSMB,1,P2,No Intervention Arm
0,19,age,<=18 years,0,B1,Hydroxychloroquine Arm
0,19,age,<=18 years,0,B2,No Intervention Arm
0,19,age,<=18 years,0,B3,Total
0,19,age,Between 18 and 65 years,0,B1,Hydroxychloroquine Arm
0,19,age,Between 18 and 65 years,1,B2,No Intervention Arm
0,19,age,Between 18 and 65 years,1,B3,Total
0,19,age,>=65 years,0,B1,Hydroxychloroquine Arm
0,19,age,>=65 years,0,B2,No Intervention Arm
0,19,age,>=65 years,0,B3,Total
0,19,"sex: female, male",Female,0,B1,Hydroxychloroquine Arm
0,19,"sex: female, male",Female,0,B2,No Intervention Arm
0,19,"sex: female, male",Female,0,B3,Total
0,19,"sex: female, male",Male,0,B1,Hydroxychloroquine Arm
0,19,"sex: female, male",Male,1,B2,No Intervention Arm
0,19,"sex: female, male",Male,1,B3,Total
0,19,enrollment region,United States,1,B2,No Intervention Arm
0,19,enrollment region,United States,1,B3,Total
0,20,milestone,STARTED,128,P1,Standard Care
0,20,milestone,STARTED,134,P2,Proxalutamide + Standard Care
0,20,milestone,COMPLETED,128,P1,Standard Care
0,20,milestone,COMPLETED,134,P2,Proxalutamide + Standard Care
0,20,milestone,NOT COMPLETED,0,P1,Standard Care
0,20,milestone,NOT COMPLETED,0,P2,Proxalutamide + Standard Care
0,20,"sex: female, male",Female,0,B1,Standard Care
0,20,"sex: female, male",Female,0,B2,Proxalutamide + Standard Care
0,20,"sex: female, male",Female,0,B3,Total
0,20,"sex: female, male",Male,128,B1,Standard Care
0,20,"sex: female, male",Male,134,B2,Proxalutamide + Standard Care
0,20,"sex: female, male",Male,262,B3,Total
0,20,enrollment region,Brazil,128,B1,Standard Care
0,20,enrollment region,Brazil,134,B2,Proxalutamide + Standard Care
0,20,enrollment region,Brazil,262,B3,Total
0,21,milestone,STARTED,10,P1,EXO-1
0,21,milestone,STARTED,10,P2,EXO-2
0,21,milestone,STARTED,10,P3,Placebo
0,21,milestone,COMPLETED,10,P1,EXO-1
0,21,milestone,COMPLETED,10,P2,EXO-2
0,21,milestone,COMPLETED,10,P3,Placebo
0,21,milestone,NOT COMPLETED,0,P1,EXO-1
0,21,milestone,NOT COMPLETED,0,P2,EXO-2
0,21,milestone,NOT COMPLETED,0,P3,Placebo
0,21,age,<=18 years,0,B1,EXO-1
0,21,age,<=18 years,0,B2,EXO-2
0,21,age,<=18 years,0,B3,Placebo
0,21,age,<=18 years,0,B4,Total
0,21,age,Between 18 and 65 years,10,B1,EXO-1
0,21,age,Between 18 and 65 years,10,B2,EXO-2
0,21,age,Between 18 and 65 years,10,B3,Placebo
0,21,age,Between 18 and 65 years,30,B4,Total
0,21,age,>=65 years,0,B1,EXO-1
0,21,age,>=65 years,0,B2,EXO-2
0,21,age,>=65 years,0,B3,Placebo
0,21,age,>=65 years,0,B4,Total
0,21,"sex: female, male",Female,6,B1,EXO-1
0,21,"sex: female, male",Female,8,B2,EXO-2
0,21,"sex: female, male",Female,5,B3,Placebo
0,21,"sex: female, male",Female,19,B4,Total
0,21,"sex: female, male",Male,4,B1,EXO-1
0,21,"sex: female, male",Male,2,B2,EXO-2
0,21,"sex: female, male",Male,5,B3,Placebo
0,21,"sex: female, male",Male,11,B4,Total
0,21,enrollment region,Russia,10,B1,EXO-1
0,21,enrollment region,Russia,10,B2,EXO-2
0,21,enrollment region,Russia,10,B3,Placebo
0,21,enrollment region,Russia,30,B4,Total
0,22,milestone,STARTED,180,P1,Control Group
0,22,milestone,STARTED,360,P2,Intervention Group
0,22,milestone,COMPLETED,151,P1,Control Group
0,22,milestone,COMPLETED,349,P2,Intervention Group
0,22,milestone,NOT COMPLETED,29,P1,Control Group
0,22,milestone,NOT COMPLETED,11,P2,Intervention Group
0,22,withdrawal reason,Withdrawal by Subject,10,P1,Control Group
0,22,withdrawal reason,Withdrawal by Subject,5,P2,Intervention Group
0,22,withdrawal reason,developed fever > 3 days,4,P1,Control Group
0,22,withdrawal reason,developed fever > 3 days,1,P2,Intervention Group
0,22,withdrawal reason,Protocol Violation,11,P1,Control Group
0,22,withdrawal reason,Protocol Violation,2,P2,Intervention Group
0,22,withdrawal reason,Lost to Follow-up,4,P1,Control Group
0,22,withdrawal reason,Lost to Follow-up,3,P2,Intervention Group
0,22,age,<=18 years,0,B1,Supportive Arm
0,22,age,<=18 years,0,B2,HCQ Arm
0,22,age,<=18 years,0,B3,Total
0,22,age,Between 18 and 65 years,180,B1,Supportive Arm
0,22,age,Between 18 and 65 years,360,B2,HCQ Arm
0,22,age,Between 18 and 65 years,540,B3,Total
0,22,age,>=65 years,0,B1,Supportive Arm
0,22,age,>=65 years,0,B2,HCQ Arm
0,22,age,>=65 years,0,B3,Total
0,22,"sex: female, male",Female,10,B1,Supportive Arm
0,22,"sex: female, male",Female,24,B2,HCQ Arm
0,22,"sex: female, male",Female,34,B3,Total
0,22,"sex: female, male",Male,170,B1,Supportive Arm
0,22,"sex: female, male",Male,336,B2,HCQ Arm
0,22,"sex: female, male",Male,506,B3,Total
0,22,enrollment region,Pakistan,180,B1,Supportive Arm
0,22,enrollment region,Pakistan,360,B2,HCQ Arm
0,22,enrollment region,Pakistan,540,B3,Total
0,23,milestone,STARTED,200,P1,Ivermectin and Doxycycline
0,23,milestone,STARTED,200,P2,Placebo
0,23,milestone,COMPLETED,183,P1,Ivermectin and Doxycycline
0,23,milestone,COMPLETED,180,P2,Placebo
0,23,milestone,NOT COMPLETED,17,P1,Ivermectin and Doxycycline
0,23,milestone,NOT COMPLETED,20,P2,Placebo
0,23,withdrawal reason,Lost to Follow-up,15,P1,Ivermectin and Doxycycline
0,23,withdrawal reason,Lost to Follow-up,17,P2,Placebo
0,23,withdrawal reason,Death,0,P1,Ivermectin and Doxycycline
0,23,withdrawal reason,Death,3,P2,Placebo
0,23,withdrawal reason,Adverse Event,2,P1,Ivermectin and Doxycycline
0,23,withdrawal reason,Adverse Event,0,P2,Placebo
0,23,"sex: female, male",Female,77,B1,Ivermectin and Doxycycline
0,23,"sex: female, male",Female,88,B2,Placebo
0,23,"sex: female, male",Female,165,B3,Total
0,23,"sex: female, male",Male,123,B1,Ivermectin and Doxycycline
0,23,"sex: female, male",Male,112,B2,Placebo
0,23,"sex: female, male",Male,235,B3,Total
0,24,milestone,STARTED,81,P1,Adult Patients Hospitalized With COVID-19
0,24,milestone,COMPLETED,81,P1,Adult Patients Hospitalized With COVID-19
0,24,milestone,NOT COMPLETED,0,P1,Adult Patients Hospitalized With COVID-19
0,24,age,<=18 years,0,B1,Adult Patients Hospitalized With COVID-19
0,24,age,Between 18 and 65 years,71,B1,Adult Patients Hospitalized With COVID-19
0,24,age,>=65 years,10,B1,Adult Patients Hospitalized With COVID-19
0,24,"sex: female, male",Female,44,B1,Adult Patients Hospitalized With COVID-19
0,24,"sex: female, male",Male,37,B1,Adult Patients Hospitalized With COVID-19
0,24,race (nih/omb),American Indian or Alaska Native,0,B1,Adult Patients Hospitalized With COVID-19
0,24,race (nih/omb),Asian,0,B1,Adult Patients Hospitalized With COVID-19
0,24,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B1,Adult Patients Hospitalized With COVID-19
0,24,race (nih/omb),Black or African American,4,B1,Adult Patients Hospitalized With COVID-19
0,24,race (nih/omb),White,77,B1,Adult Patients Hospitalized With COVID-19
0,24,race (nih/omb),More than one race,0,B1,Adult Patients Hospitalized With COVID-19
0,24,race (nih/omb),Unknown or Not Reported,0,B1,Adult Patients Hospitalized With COVID-19
0,24,enrollment region,Belarus,10,B1,Adult Patients Hospitalized With COVID-19
0,24,enrollment region,Russia,71,B1,Adult Patients Hospitalized With COVID-19
0,24,baseline severity according to the national early warning score (news score),Very Severe (NEWS ≥ 9),30,B1,Adult Patients Hospitalized With COVID-19
0,24,baseline severity according to the national early warning score (news score),Severe or Moderate (NEWS = 5…8),28,B1,Adult Patients Hospitalized With COVID-19
0,24,baseline severity according to the national early warning score (news score),Mild (NEWS ≤ 4),23,B1,Adult Patients Hospitalized With COVID-19
0,24,respiratory support type,Invasive lung ventilation,14,B1,Adult Patients Hospitalized With COVID-19
0,24,respiratory support type,Non-invasive lung ventilation,25,B1,Adult Patients Hospitalized With COVID-19
0,24,respiratory support type,Oxygen therapy,25,B1,Adult Patients Hospitalized With COVID-19
0,24,respiratory support type,None,17,B1,Adult Patients Hospitalized With COVID-19
0,24,mechanical ventilation,Present,39,B1,Adult Patients Hospitalized With COVID-19
0,24,mechanical ventilation,Absent,42,B1,Adult Patients Hospitalized With COVID-19
0,25,milestone,STARTED,100,P1,Favipiravir (Areplivir)
0,25,milestone,STARTED,100,P2,Standard of Care
0,25,milestone,COMPLETED,96,P1,Favipiravir (Areplivir)
0,25,milestone,COMPLETED,100,P2,Standard of Care
0,25,milestone,NOT COMPLETED,4,P1,Favipiravir (Areplivir)
0,25,milestone,NOT COMPLETED,0,P2,Standard of Care
0,25,withdrawal reason,The need for prohibited therapy,2,P1,Favipiravir (Areplivir)
0,25,withdrawal reason,The need for prohibited therapy,0,P2,Standard of Care
0,25,withdrawal reason,Adverse Event,1,P1,Favipiravir (Areplivir)
0,25,withdrawal reason,Adverse Event,0,P2,Standard of Care
0,25,withdrawal reason,Protocol Violation,1,P1,Favipiravir (Areplivir)
0,25,withdrawal reason,Protocol Violation,0,P2,Standard of Care
0,25,"sex: female, male",Female,49,B1,Favipiravir (Areplivir)
0,25,"sex: female, male",Female,54,B2,Standard of Care
0,25,"sex: female, male",Female,103,B3,Total
0,25,"sex: female, male",Male,51,B1,Favipiravir (Areplivir)
0,25,"sex: female, male",Male,46,B2,Standard of Care
0,25,"sex: female, male",Male,97,B3,Total
0,25,enrollment region,Russia,100,B1,Favipiravir (Areplivir)
0,25,enrollment region,Russia,100,B2,Standard of Care
0,25,enrollment region,Russia,200,B3,Total
0,26,milestone,STARTED,30,P1,Control Group
0,26,milestone,STARTED,36,P2,Study Group
0,26,milestone,COMPLETED,30,P1,Control Group
0,26,milestone,COMPLETED,30,P2,Study Group
0,26,milestone,NOT COMPLETED,0,P1,Control Group
0,26,milestone,NOT COMPLETED,6,P2,Study Group
0,26,withdrawal reason,Mutation disrupting ivermectin metabolism was found in 6 patients,0,P1,Control Group
0,26,withdrawal reason,Mutation disrupting ivermectin metabolism was found in 6 patients,6,P2,Study Group
0,26,"sex: female, male",Female,11,B1,Control Group
0,26,"sex: female, male",Female,9,B2,Study Group
0,26,"sex: female, male",Female,20,B3,Total
0,26,"sex: female, male",Male,19,B1,Control Group
0,26,"sex: female, male",Male,21,B2,Study Group
0,26,"sex: female, male",Male,40,B3,Total
0,26,race (nih/omb),American Indian or Alaska Native,0,B1,Control Group
0,26,race (nih/omb),American Indian or Alaska Native,0,B2,Study Group
0,26,race (nih/omb),American Indian or Alaska Native,0,B3,Total
0,26,race (nih/omb),Asian,0,B1,Control Group
0,26,race (nih/omb),Asian,0,B2,Study Group
0,26,race (nih/omb),Asian,0,B3,Total
0,26,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B1,Control Group
0,26,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B2,Study Group
0,26,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B3,Total
0,26,race (nih/omb),Black or African American,0,B1,Control Group
0,26,race (nih/omb),Black or African American,0,B2,Study Group
0,26,race (nih/omb),Black or African American,0,B3,Total
0,26,race (nih/omb),White,0,B1,Control Group
0,26,race (nih/omb),White,0,B2,Study Group
0,26,race (nih/omb),White,0,B3,Total
0,26,race (nih/omb),More than one race,0,B1,Control Group
0,26,race (nih/omb),More than one race,0,B2,Study Group
0,26,race (nih/omb),More than one race,0,B3,Total
0,26,race (nih/omb),Unknown or Not Reported,30,B1,Control Group
0,26,race (nih/omb),Unknown or Not Reported,30,B2,Study Group
0,26,race (nih/omb),Unknown or Not Reported,60,B3,Total
0,26,enrollment region,Turkey,30,B1,Control Group
0,26,enrollment region,Turkey,30,B2,Study Group
0,26,enrollment region,Turkey,60,B3,Total
0,27,milestone,STARTED,850,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic
0,27,milestone,COMPLETED,813,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic
0,27,milestone,NOT COMPLETED,37,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic
0,27,withdrawal reason,with missing data,37,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic
0,27,age,<=18 years,0,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals
0,27,age,Between 18 and 65 years,813,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals
0,27,age,>=65 years,0,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals
0,27,"sex: female, male",Female,553,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals
0,27,"sex: female, male",Male,260,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals
0,27,race (nih/omb),American Indian or Alaska Native,0,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals
0,27,race (nih/omb),Asian,0,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals
0,27,race (nih/omb),Native Hawaiian or Other Pacific Islander,0,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals
0,27,race (nih/omb),Black or African American,0,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals
0,27,race (nih/omb),White,813,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals
0,27,race (nih/omb),More than one race,0,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals
0,27,race (nih/omb),Unknown or Not Reported,0,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals
0,27,enrollment region,Turkey,813,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals
